- Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
- Elicio Therapeutics Announces Proposed Public Offering
- Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
- Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
- Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
- Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
- Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
- Elicio Therapeutics Announces $7.0 Million Private Placement Financing
More ▼
Key statistics
On Wednesday, Elicio Therapeutics Inc (ELTX:NMQ) closed at 3.68, 24.32% above the 52 week low of 2.96 set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.54 |
---|---|
High | 3.77 |
Low | 3.50 |
Bid | 3.42 |
Offer | 3.96 |
Previous close | 3.39 |
Average volume | 96.30k |
---|---|
Shares outstanding | 10.27m |
Free float | 6.79m |
P/E (TTM) | -- |
Market cap | 37.79m USD |
EPS (TTM) | -6.63 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼